{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"51"}]}],"title":"Normal ECG Evaluation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"64"}]}],"title":"Abnormal ECG Evaluation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"},{"groupId":"OG001","value":"264"},{"groupId":"OG002","value":"114"},{"groupId":"OG003","value":"115"}],"units":"Participants"}],"groups":[{"description":"High risk prostate cancer participants planned for radical prostatectomy with pelvic lymph node dissection (Cohort A) were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection. Participants had a 12-lead electrocardiogram (ECG) taken on the day of dosing, prior to dosing.","id":"OG000","title":"High Risk Prostate Cancer (Cohort A) - Baseline ECG"},{"description":"High risk prostate cancer participants planned for radical prostatectomy with pelvic lymph node dissection (Cohort A) were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection. Participants had a 12-lead electrocardiogram (ECG) taken after dosing and prior to imaging.","id":"OG001","title":"High Risk Prostate Cancer (Cohort A) - Post-dosing ECG"},{"description":"Participants with presumptive radiologic evidence of prostate cancer recurrence or metastasis on conventional imaging and planned for conventional image-guided biopsy (Cohort B) were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection.","id":"OG002","title":"Recurrent or Metastatic Prostate Cancer (Cohort B) - Baseline ECG"},{"description":"Participants with presumptive radiologic evidence of prostate cancer recurrence or metastasis on conventional imaging and planned for conventional image-guided biopsy (Cohort B) were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection. Participants had a 12-lead electrocardiogram (ECG) taken after dosing and prior to imaging.","id":"OG003","title":"Recurrent or Metastatic Prostate Cancer (Cohort B) - Post-dosing ECG"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Set includes all participants who received any amount of 18F-DCFPyL and have reported data (i.e., some participants had missing ECG measurements).","reportingStatus":"POSTED","timeFrame":"Changes in ECG pre-drug dosing and within 1-2 hours post-dosing","title":"Changes From Baseline in Electrocardiogram (ECG) Parameters (Safety Outcome Measure)","type":"SECONDARY","unitOfMeasure":"Participants"}